Sector News

Actavis job-cutting drive hits 400-plus on Long Island

March 18, 2015
Life sciences
New-look Actavis–soon to be Allergan–has been undergoing plenty of changes since it agreed in November to shell out $66 billion for the Botox maker. And as it continues to integrate Allergan’s ops, it’s shaving away at the workforce it inherited from its prior pickup, Forest Labs.
 
Last week, the company updated its Long Island, NY, jobs toll to 412, with the bulk of those in commercial packaging operations. Forty-seven of the job-cutting total are sales staffers who work remotely, according to a New York state WARN notice.
 
Actavis first announced the layoffs back in September, and since then it’s gotten to work trimming Forest’s ranks in other states, too. Last July, it delivered pink slips to 190 workers in Earth City, MO, after deciding to close a facility there. And in December, it said it would cut loose 200 more in Corona, CA, an area that’s been part of a gradual drawdown.
 
What Actavis hasn’t yet said, though, is whether, which and when employees will face the ax as a result of its Allergan tie-up. The deal, which added 11,500 staffers to the 25,000 employees Actavis already had, closed this week after clearing its final regulatory hurdle
 
But word on any forthcoming scale-back could be coming sooner rather than later. The Dublin drugmaker has pledged $1.8 billion in cost savings–the majority of which are due within the next year.
 
By Carly Helfand
 

comments closed

Related News

February 25, 2024

Pharma CFOs need R&D vigilance in tough economic times

Life sciences

As inflation, high interest rates and a tight investment environment continue to create headaches, 72% of CFOs said economic volatility poses the same or greater risk to their business this year compared to 2023 in a recent survey from BDO — and there are more changes afoot.

February 25, 2024

Agilent CEO Mike McMullen to retire, succeeded by lab services head

Life sciences

McMullen, who’s also currently president of Agilent, is set to abdicate both roles on May 1, according to an announcement the company put out Wednesday afternoon. From there, McMullen will spend a few months serving as an advisor to Agilent and to his successor until his retirement becomes final on Oct. 31.

February 25, 2024

AstraZeneca completes Gracell Biotechnologies acquisition for $1.2bn

Life sciences

AstraZeneca has concluded its acquisition of China-based clinical-stage biopharmaceutical company Gracell Biotechnologies for $1.2bn. The acquisition, initially agreed in December 2023, positions Gracell as a wholly owned AstraZeneca subsidiary with operations continuing in the US and China.

How can we help you?

We're easy to reach